Loading...
Sorafenib, a multitargeted tyrosine kinase inhibitor, is the standard therapy for advanced hepatocellular cancer, but it has only a modest impact on survival.
Investigators now report results of an industry-sponsored, international, multicenter, randomized, open-label, phase III trial that compares sorafenib with linifanib, a new multitargeted tyrosine kinase inhibitor, in 1035 patients (median age, 60 years) with unresectable or metastatic hepatocellular cancer. Most patients were male (85%) and Asian (67%) and had hepatitis B virus infection (53%), Child-Pugh Class A liver function (94%), and performance status 0 (64%).
Overall survival (the primary endpoint) was not improved with linifanib versus sorafenib (9.1 and 9.8 months, respectively…